Table 3 Residual effects of Braak stage after adjustment for plaque core.

From: Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study

APOE

Compared to APOE2/3

Compared to APOE3/3

Compared to APOE4/4

BETA

SE

P

BETA

SE

P

BETA

SE

P

2/2

−0.44

0.31

0.15

−0.50

0.28

0.07

−1.32

0.27

1.6 × 10−6

2/3

Ref.

Ref.

Ref.

−0.07

0.09

0.44

−0.43

0.11

1.2 × 10−4

3/3

0.07

0.09

0.39

Ref.

Ref.

Ref.

−0.25

0.06

4.3 × 10−5

2/4

0.13

0.16

0.40

0.03

0.12

0.80

−0.26

0.11

0.02

3/4

0.29

0.08

6.1 × 10−4

0.15

0.04

1.9 × 10−4

−0.10

0.05

0.05

4/4

0.42

0.10

7.5 × 10−5

0.25

0.06

4.3 × 10−5

Ref.

Ref.

Ref.

  1. β estimate (BETA), standard error (SE), and P (P value) for each APOE genotype compared to the APOE2/3, 3/3, and 4/4 genotype as a reference (Ref.) were calculated under a linear regression model; NA: not applicable. β estimates reflect the impact of each APOE genotype on Braak (tau tangle) stage after adjustment for CERAD (neuritic Aβ plaque) score.
Back to article page